Download PDF
Thromb Haemost 1989; 62(03): 950-954
DOI: 10.1055/s-0038-1651034
Original Article
Schattauer GmbH Stuttgart

The Effect of Calcium Chloride on Anti-Xa Activity of Heparin and Its Molecular Weight Fractions

T W Barrowcliffe
The National Institute for Biological Standards and Control, Potters Bar, Herts., U. K.
,
Yvonne Le Shirley
The National Institute for Biological Standards and Control, Potters Bar, Herts., U. K.
› Author Affiliations
Further Information

Publication History

Received: 07 June 1989

Accepted after revision 26 July 1989

Publication Date:
30 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The anti-Xa activities of unfractionated heparin (UFH) and nine low molecular weight heparins (LMWH) have been measured in the presence and absence of 3 mM CaCl2, using bovine Factor Xa, purified human AT III and an amidolytic assay. The addition of CaCl2 increased the activity of UFH by 93%, but the effect on LMWH was less, ranging from −20% to +55%. Studies of gel filtration fractions of UFH showed marked Mr dependence of the CaCl2 effect in the range 4,000-12,000. The differences among the various LMW heparins with respect to the effect of CaCl2 were closely correlated with the amount of polysaccharide above an Mr of 6,500. Kinetic studies confirmed the potentiation of the activity of UFH with bovine Xa and showed an even more marked effect using human Xa.

Keywords

Heparin - LMW heparin - Anti-Xa
 

  • References

  • 1 Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Sims GE C. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thrombos Res 1976; 9: 575-583
    CrossrefPubMedGoogle Scholar
  • 2 Lane DA, MacGregor IR, Michalski R, Kakkar VV. Anticoagulant activities of four unfractionated and fractionated heparins. Thromb Res 1978; 12: 257-271
    CrossrefPubMedGoogle Scholar
  • 3 Barrowcliffe TW, Johnson EA, Eggleton C, Kemball-Cook G, Thomas DR. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haematol 1979; 41: 573-583
    CrossrefPubMedGoogle Scholar
  • 4 Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Soderstrom G. Molecular weight dependency of the heparin potentiated inhibitor of thrombin and activated Factor X. Effect of heparin neutralization in plasma. Thromb Res 1979; 15: 531-541
    CrossrefPubMedGoogle Scholar
  • 5 Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralisation by platelet factor 4. Biochem J 1984; 218: 725-732
    CrossrefPubMedGoogle Scholar
  • 6 Kakkar VV, Murray WJ G. Efficacy and safety of low molecular weight heparin (CY216) in preventing postoperative venous thromboembolism: a cooperative study. Br J Surg 1985; 72: 786-791
    CrossrefPubMedGoogle Scholar
  • 7 Roller M, Schoch U, Buchmann P. et al. Low molecular weight heparin (KABI-2165) as thromboprophylaxis in elective visceral surgery. Thromb Haemostas 1986; 56: 243-246
    PubMedGoogle Scholar
  • 8 Schmitz-Huebner U, Bunte H, Freise G. et al. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wochenschr 1984; 62: 349-353
    CrossrefPubMedGoogle Scholar
  • 9 Turpie AG G, Levine MN, Hirsh J. et al. A randomised controlled trial of KP1069 low molecular weight heparin in the prevention of deep vein thrombosis in patients undergoing elective hip surgery. New Engl J Med 1986; 315: 925-929
    CrossrefPubMedGoogle Scholar
  • 10 Bergqvist D, Burmark US, Frisell J. et al. Low molecular weight heparin once daily compared with conventional low dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986; 73: 204-208
    CrossrefPubMedGoogle Scholar
  • 11 Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajchman MA, Hirsh J. The inhibition of thrombin-dependent feedback reactions is critical to the expression of the anticoagulant effects of heparin. Biochem J 1987; 243: 579-588
    CrossrefPubMedGoogle Scholar
  • 12 Beguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemostas 1988; 60: 457-462
    PubMedGoogle Scholar
  • 13 Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb Haemostas 1982; 47: 244-248
    PubMedGoogle Scholar
  • 14 Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
    CrossrefPubMedGoogle Scholar
  • 15 Ockelford PA, Carter CJ, Mitchell L, Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res 1982; 28: 401-409
    CrossrefPubMedGoogle Scholar
  • 16 Buchanan MR, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
    PubMedGoogle Scholar
  • 17 Fernandex FA, Buchanan MR, Hirsh J, Fenton JW, Ofosu FA. Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits. Thromb Haemostas 1987; 57: 286-293
    PubMedGoogle Scholar
  • 18 Levine MN, Hirsh J. An overview of clinical trials of low molecular weight heparin fractions. Acta Chir Scand Suppl 1988; 543: 73-79
    PubMedGoogle Scholar
  • 19 Lockner D. A comparison between low molecular weight heparin (KABI-2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemostas 1985; 54: 813-817
    PubMedGoogle Scholar
  • 20 Tew CJ, Lane DA, Thompson E, Ireland H, Curtis JR. Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY222. Br J Haematol 1988; 70: 335-340
    CrossrefPubMedGoogle Scholar
  • 21 Miletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding site on human platelets. J Biol Chem 1978; 253: 6908-6916
    PubMedGoogle Scholar
  • 22 Teitel JM, Rosenberg RD. Protection of factor Xa from neutralisation by the heparin-antithrombin complex. Clin Invest 1983; 71: 1383-1391
    CrossrefPubMedGoogle Scholar
  • 23 Ofosu FA, Cerskus AL, Hirsh J, Smith LM, Modi GJ, Blajchman MA. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids and tissue factor. Br J Haematol 1984; 57: 229-238
    CrossrefPubMedGoogle Scholar
  • 24 Ellis V, Scully MF, Kakkar VV. The acceleration of the inhibition of platelet prothrombinase complex by heparin. Biochem J 1986; 233: 161-165
    CrossrefPubMedGoogle Scholar
  • 25 Barrowcliffe TW, Havercroft SJ, Kemball-Cook G, Lindahl U. The effect of Ca2+, phospholipid and Factor V on the anti-(Factor Xa) activity of heparin and its high-affinity oligosaccharides. Biochem J 1987; 243: 31-37
    CrossrefPubMedGoogle Scholar
  • 26 Thomas DP, Curtis AD, Barrowcliffe TW. A collaborative study designed to establish the 4th International Standard for heparin. Thromb Haemostas 1984; 52: 148-153
    PubMedGoogle Scholar
  • 27 Barrowcliffe TW, Curtis AD, Tomlinson TP, Hubbard AR, Johnson EA, Thomas DP. Standardization of low molecular heparins: a collaborative study. Thromb Haemostas 1985; 54: 675-679
    PubMedGoogle Scholar
  • 28 Barrowcliffe TW, Curtis AD, Thomas DP. An International Standard for low molecular weight heparin. Thromb Haemostas 1988; 60: 1-7
    PubMedGoogle Scholar
  • 29 Johnson EA, Mulloy B. The molecular weight range of mucosal heparin preparations. Carbohydr Res 1976; 51: 119-127
    CrossrefPubMedGoogle Scholar
  • 30 Johnson EA. An approach to a molecular weight calibration for low molecular weight heparins. Thromb Res 1987; 45: 675-680
    CrossrefPubMedGoogle Scholar
  • 31 Biggs R, Denson KW E, Akman N, Borrett R, Hadden M. Antithrombin III, anti-factor Xa and heparin. Br J Haematol 1970; 19: 283-305
    CrossrefPubMedGoogle Scholar
  • 32 Long WF, Williamson FB. Potentiation by calcium ions of the antithrombin III inhibition of thrombin. Biochem Biophys Res Comm 1982; 104: 363-368
    CrossrefPubMedGoogle Scholar
  • 33 Pomerantz MW, Owen WG. A catalytic role for heparin. Evidence for a ternary complex of heparin co-factor, thrombin and heparin. Biochim Biophys Acta 1978; 535: 66-77
    CrossrefPubMedGoogle Scholar
  • 34 Sherrill GB, Meade JB, Kalayanamit T, Monroe DM, Church FC. Calcium enhances factor Xa activity independent of gamma-carboxy-glutamic acid residues. Thromb Res 1988; 52: 53-60
    CrossrefPubMedGoogle Scholar
  • 35 Machovich R, Regoeczi E, Hatton MW C. The influence of heparin, NaCl and CaCl2 on the rate of the thrombin-antithrombin III reaction. Thromb Res 1979; 15: 821-834
    CrossrefPubMedGoogle Scholar
  • 36 Lundblad RL, Roberts JC, Johnson DK, Featherstone GL, Griffith MJ. Acceleration by calcium of the inactivation of thrombin by plasma proteinase inhibitors. Thromb Res 1981; 22: 135-146
    CrossrefPubMedGoogle Scholar
  • 37 Oosta GM, Gardner WT, Beeler DL, Rosenberg RD. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci USA 1981; 78: 829-833
    CrossrefPubMedGoogle Scholar
  • 38 Pieters J, Williams G, Hemker HC, Lindhout T. Inhibition of factor IXa and factor Xa by antithrombin III/heparin during factor X activation. J Biol Chem 1988; 263 (30) 15313-15318
    PubMedGoogle Scholar